MetaCap

INmune Bio (INMB) vs Genenta Science S.p.A. (SAEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

INmune Bio is the larger company by market cap ($25.6 million vs $24.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INMB-37.35%SAEN-47.19%
+3%-23%-50%
Nov 3, 20261 yearNov 20, 2026
INMB-26.81%SAEN-23.70%
+1%-13%-28%
Nov 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INMB versus SAEN key metrics
MetricINMBSAEN
Share price$0.827$0.5074
Market cap$25.60M$24.47M
1-day change-7.50%-9.39%
YTD return-46.99%—
1-year return-45.23%—
5-year return-93.80%—
EPS (TTM)$-0.60$-0.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$50.00K—
Revenue growth (YoY)+257.14%—
Net income (latest FY)$-45.93M—
Operating margin-94766.00%—
Net margin-91866.00%—
52-week high$2.60$2.58
52-week low$0.8189$0.50
Distance from 52-week high-68.19%-80.33%
Analyst consensusstrong_buy—
Avg. price target upside+746.43%—
Average volume338.47K85.01K
Shares outstanding30.96M48.22M
Employees219
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About INmune Bio

INMB stock →

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees

About Genenta Science S.p.A.

SAEN stock →

Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees

INMB vs SAEN FAQ

Which is bigger, INmune Bio or Genenta Science S.p.A.?

INmune Bio (INMB) is larger, with a market capitalization of $25.60M compared with $24.47M for Genenta Science S.p.A. (SAEN).

Are INmune Bio and Genenta Science S.p.A. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons